Abstract
Introduction
In stereotactic radiosurgery (SRS) for brain metastasis (BM), the target dose inhomogeneity remains highly variable among modalities, irradiation techniques, and facilities, which can affect tumor response during and after multi-fraction SRS. Volumetric-modulated arcs (VMAs) can provide a concentrically-layered steep dose increase inside a gross tumor volume (GTV) boundary compared to dynamic conformal arcs. This study was conducted to review the optimal evaluation method for the internal GTV doses relevant to maximal response and local control, specifically to examine the significance of the doses 2 mm and 4 mm inside the GTV boundary in VMA-based SRS.
Materials and methods
This was a planning study for the clinical scenario of a single BM and targeted 25 GTVs of >0.50 cc, including eight spherical models with diameters of 10-45 mm and 17 clinical BMs (GTV: 0.72-44.33 cc). SRS plans were generated for each GTV using VMA with a 5-mm leaf-width multileaf collimator and the optimization that prioritized the steepness of the dose gradient outside the GTV boundary without any internal dose constraints. The dose prescription and evaluation were based on the GTV DV-0.01 cc, a minimum dose of GTV minus 0.01 cc. Two planning systems were compared for the GTV - 2 mm and GTV - 4 mm structures that were generated by equally reducing 2 mm and 4 mm from the GTV surface. The DeIIVs, a minimum dose of the irradiated isodose volume equivalent to the GTV - 2 mm and GTV - 4 mm, were compared to other common metrics.
Results
The GTV - 2 mm and GTV - 4 mm volumes differed significantly between the systems. In the spherical GTVs, the irradiated isodose surfaces of GTV D80% and D50% corresponded to 0.4-1.6 mm (<2 mm) and 1.0-4.6 mm inside the GTV boundary, respectively. In the 25 GTVs, the GTV - 2 mm coverage with the DeIIV varied from 83.7% to 98.2% (95-98% in 68% of the cases), while the GTV coverage with the GTV - 2 mm DeIIV was 20.2-75.9%. In the 23 GTVs of ≥1.26 cc, the GTV coverage with the GTV - 4 mm DeIIV varied from 1.9% to 55.6% (<50% in 87% of the cases). No significant difference was observed between the GTV D50% and the GTV - 2 mm DeIIV, while the GTV - 4 mm DeIIV was significantly higher than the GTV D50%. No significant correlations were observed between the GTV D50% and the DeIIVs of the GTV - 2 mm and GTV - 4 mm.
Conclusions
The doses 2 mm and 4 mm inside a GTV have low correlations with the GTV D50% and may be more relevant to maximal response and local control for SRS of BM. The DeIIV instead of the minimum dose of a fixed % coverage (e.g. D98%) is suitable for reporting the doses 2 mm and 4 mm inside the GTV boundary in terms of avoiding the over- or under-coverage, with consideration to substantial variability in minus margin addition functions among planning systems. In VMA-based SRS with a steep dose gradient, the doses 2-4 mm inside a GTV decrease significantly as the GTV increases, which can attenuate the excessive dose exposure to the surrounding brain in a large BM due to the GTV shrinkage during multi-fraction SRS.
Keywords: dose evaluation, maximal tumor response, local control, gross tumor volume, biologically effective dose, volumetric-modulated arc therapy, dose inhomogeneity, dose gradient, brain metastasis, stereotactic radiosurgery
Introduction
Stereotactic radiosurgery (SRS) is an indispensable therapeutic avenue for brain metastases (BMs), and its indication has been expanded to large (>3 cm) and/or multiple (>10) lesions, with the increasing leverage of frameless multi-fraction irradiation [1-3]. SRS has been performed in a variety of devices and techniques, in which the target dose heterogeneities range from homogeneous to extremely inhomogeneous, with significant variability among facilities [4,5]. Especially in multi-fraction SRS, even if the marginal dose of a gross tumor volume (GTV) is the same, the differences in the dose gradient inside the GTV boundary can lead to differences in the degree of tumor shrinkage, maximal response, and its durability during and after multi-fraction SRS [6,7]. Extremely inhomogeneous target dose and/or intentional internal dose escalation can contribute to excellent maximum response (reduction rate) and local control [8-15]. Specifically, the volume irradiated with ≥30 Gy (one fraction) in a GTV is large [8,10], and the GTV D80%, a minimum dose to cover 80% of a GTV, is high [12].
A GTV internal dose (dose inhomogeneity) was traditionally reported only in terms of the marginal dose and central (maximum) dose [5]. Subsequently, evaluation with the D98% (or DV-0.035 cc for <2 cc), D50%, and D2% (or D0.035 cc for <2 cc) has been recommended [16]. With the same equipment and irradiation technique, even if the GTV marginal dose and maximum dose are the same, the dose gradient several millimeters inward from the GTV boundary will vary considerably depending on the planning method [4,6,7]. Therefore, it is necessary to verify whether the conventional dose evaluation method ensures the optimal representative metrics to specify the differences in these internal dose characteristics.
Dynamic conformal arcs (DCAs) and volumetric-modulated arcs (VMAs) are frequently used irradiation techniques in linac-based SRS using a multi-leaf collimator (MLC) [17,18]. In DCAs, it is necessary to specify target dose heterogeneity such as 70% isodose covering in planning [4,17]. DCAs frequently require the use of dummy structures, a modified GTV as a surrogate for MLC adaptation, to improve dose conformity [19]. In addition, with the arcs arranged exclusively in the cranial hemisphere, the high-dose areas tend to be unevenly distributed toward the cranial side of a GTV [19]. In contrast, VMAs can provide extremely inhomogeneous GTV doses suitable for individual lesions through optimization that prioritizes the steepness of dose gradient outside a GTV boundary without any internal dose constraints or without fixing GTV dose heterogeneity [7,20]. VMAs can generate a concentrically-layered steep dose gradient inside the GTV boundary with excellent dose convergence toward the center, compared to DCAs [2,7,21].
In this study, we will consider the optimal dose evaluation method to appropriately specify the difference in dose gradient inward from a GTV boundary, between the GTV boundary and its center. Specifically, we will examine the significance of evaluating the doses 2 mm and 4 mm inside the GTV boundary and the appropriate metrics in VMA-based SRS for a single BM.
Materials and methods
This was a planning study for the clinical scenarios of a single BM. The GTV for clinical BM was defined as in the previous study [20,22].
Table 1 shows the physical doses with the corresponding biologically effective doses based on the linear-quadratic formula with the alpha/beta ratio of 10 (BED10) being just over 80.00 Gy, 100.00 Gy, and 120.00 Gy in 1-10 fraction(s) [21].
Table 1. Physical doses with the BEDs 100 Gy and 120 Gy relative to a prescribed dose with the BED 80 Gy in 1-10 fractions.
BED10 | Fraction(s) | 1 fr | 3 fr | 4 fr | 5 fr | 6 fr | 8 fr | 10 fr |
BED10 80 Gy | Physical dose (BED10) | 23.73 (80.04) | 36.24 (80.02) | 40.00 (80.00) | 43.01 (80.01) | 45.50 (80.00) | 49.45 (80.02) | 52.47 (80.00) |
BED10 100 Gy | Physical dose (BED10) | 27.02 (100.03) | 41.79 (100.00) | 46.34 (100.02) | 50.00 (100.00) | 53.07 (100.01) | 57.98 (100.00) | 61.81 (100.01) |
Relative dose* (%) | 113.9% | 115.3% | 115.9% | 116.3% | 116.6% | 117.2% | 117.8% | |
BED10 120 Gy | Physical dose (BED10) | 30.00 (120.00) | 46.85 (120.01) | 52.11 (120.00) | 56.40 (120.02) | 60.00 (120.00) | 65.83 (120.00) | 70.42 (120.01) |
Relative dose* (%) | 126.4% | 129.3% | 130.3% | 131.1% | 131.9% | 133.1% | 134.2% |
Table 2 shows the BED10 of physical doses equivalent to 125% and 150% of a prescribed dose with the BED10 80 Gy in 1-10 fraction(s).
Table 2. BED10 of the physical doses equivalent to 125% and 150% of a prescribed dose with the BED10 80 Gy in 1-10 fractions.
Relative dose | Fraction(s) | 1 fr | 3 fr | 4 fr | 5 fr | 6 fr | 8 fr | 10 fr |
125% | Physical dose (BED10) | 29.66 (117.65) | 45.30 (113.70) | 50.00 (112.50) | 53.76 (111.57) | 56.88 (110.79) | 61.81 (109.57) | 65.59 (108.60) |
150% | Physical dose (BED10) | 35.60 (162.30) | 54.36 (152.86) | 60.00 (150.00) | 64.52 (147.76) | 68.25 (145.88) | 74.18 (142.95) | 78.71 (140.65) |
The physical doses (%) of the BED10 100 Gy and 120 Gy, relative to those of the BED10 80 Gy (100%), definitely increase as the number of dose fractions increases (Table 1). In dose prescription with the BED10 80 Gy to a GTV boundary with the same dose gradient inside the GTV, the internal BED10 steadily decreases with increasing the number of fractions (Table 2). Thus, the internal BED10 of a GTV decreases with increasing dose fractionation when the GTV dose inhomogeneity is equal.
Eight sphere structures with diameters ranging from 10 to 45 mm with a 5-mm increment were generated using a sphere drawing tool by MIM Maestro® version 7.1.3 (MIM Software Inc., Cleveland, Ohio, USA) and were assumed as GTVs as in the previous study [7,22]. The head computed tomography (CT) images (voxel size 0.98 x 0.98 x 1 mm) and GTV localization (the right lateral thalamus) used were identical to those employed in the previous study [7,20,22]. Additionally, 17 clinical BMs of various volumes (>0.50 cc, 0.72-44.33 cc) were selected, and each original GTV was treated as a single lesion. Thus, a total of 25 GTVs were included in this study.
Each GTV was equally reduced by 2 mm and 4 mm using two planning systems, MIM Maestro and Monaco® version 5.51.10 (Elekta AB, Stockholm, Sweden) by adding the same minus margin to the GTV, to generate the GTV - 2 mm and GTV - 4 mm structures, respectively [22]. The two types of GTV - 2 mm and GTV - 4 mm were compared, together with the calculated values for the sphere GTVs. The changes in these target volumes on the dose-volume histogram (DVH) in Monaco were also compared.
SRS plans were generated for each GTV. The dose prescription was based on the GTV DV-0.01 cc, a minimum dose to cover a GTV minus 0.01 cc [20]. The treatment platform was a 5-mm MLC Agility® (Elekta AB, Stockholm, Sweden) mounted in a linac Infinity® (Elekta AB, Stockholm, Sweden) with a flattening filter-free mode of a 6 MV X-ray beam, which provides a dose rate of up to 1400 monitor unit per minute [20,22]. Monaco was used to optimize VMA-based SRS [7,20,22]. The isocenter localization, arc arrangement, optimization method, and dose calculation algorithm were identical to those described in the previous study [20,22]. Following the completion of optimization, each prescribed dose was rescaled according to each coverage value (>95%) of the GTV DV-0.01 cc [20].
The near-maximum dose of GTV was defined as D0.01 cc, and the GTV D0.01 cc was expressed as a relative dose to the GTV DV-0.01 cc (%) to represent the GTV dose inhomogeneity [20]. An irradiated isodose volume (IIV) of X Gy was defined as the total volume to which ≥X Gy was irradiated, including the GTV. A minimum dose to cover the IIV equivalent to a target volume on the DVH was defined as DeIIV (eIIV: equivalent IIV), an alternative to the near-minimum dose of a non-GTV target volume [22].
For statistical analyses, paired nonparametric tests were used, considering the distributions of the variables. The Spearman’s rank correlation coefficient (SRCC) was used to evaluate the correlations between two numerical variables. The Wilcoxon signed-rank test (WSRT) was used to compare two numerical variables. Significance was considered at p < 0.05 (*), p < 0.01 (**), and p < 0.001 (***).
Results
Assuming that the dose increases inward from the GTV boundary is concentrically layered in the spherical GTVs (10-45 mm), the distances of the IIV surfaces corresponding to 80% and 50% of the GTV (D80% and D50%) from the GTV boundary are shown in Figure 1A. The GTV coverage values by the GTV - 2 mm and GTV - 4 mm are shown in Figure 1B. The isodose surfaces (IDS) of the GTV D80% were 0.4-1.6 mm (<2 mm) inside the GTV boundary, while those of the GTV D50% from the GTV boundary ranged from 1.0 mm to 4.6 mm (Figure 1A). Meanwhile, the GTV coverage values of the volumes of GTV evenly reduced by 2 mm and 4 mm increased from 21.6% to 75.6% and from 0.8% to 55.6%, respectively, as the GTV increased (Figure 1B).
The differences between the GTV - 2 mm and GTV - 4 mm volumes generated by the two systems from the calculated values are shown in Figures 2A-2D, along with further volume variations in the DVHs.
The differences of the GTV - 2 mm and GTV - 4 mm volumes from the calculated values were significantly larger in Monaco than in MIM Maestro. The example of the GTV - 2 mm and GTV - 4 mm structures generated by the two systems is shown in Figure 3.
The GTV - 2 mm and GTV - 4 mm structures in Monaco tended to be smaller than the original volume, and the unevenness of the contours was more noticeable in Monaco. Therefore, subsequent analyses were performed using the GTV - 2 mm and GTV - 4 mm structures generated by MIM Maestro.
The GTV median dose (D50%) and the dose 2 mm inside the GTV boundary (GTV - 2 mm DeIIV), relative to the GTV DV-0.01 cc (100%), as a function of GTV are shown in Figure 4.
There was no significant difference between the GTV D50% and the GTV - 2 mm DeIIV (WSRT, p = 0.109). Although no significant correlation was observed between the GTV and the GTV D50% (Figure 4A), the GTV - 2 mm DeIIV decreased significantly as the GTV increased (Figure 4B).
The coverage values of the GTV - 2 mm and the GTV by the GTV - 2 mm DeIIV are shown in Figure 5.
The coverage values of the GTV - 2 mm by the GTV - 2 mm DeIIV were within the range of 95-98% in 68% of the cases, while those were <95% in 28% of the cases. The GTV coverage with the GTV - 2 mm DeIIV ranged from 20.2% to 75.9%, in which those were within the range of 50-80% in 80% of the cases.
The GTV - 2 mm D95% relative to the GTV DV-0.01 cc (100%) and the excess or deficiency of the IIV relative to the GTV - 2 mm volumes are shown in Figure 6 as a function of GTV.
The GTV - 2 mm D95% decreased significantly as the GTV increased (Figure 6A), and the correlation between the DeIIV and D95% of the GTV - 2 mm was high (SRCC: rho = 0.983, p < 0.001***). However, there was a considerable excess or deficiency in the IIV of the GTV - 2 mm D95% for the GTV - 2 mm (Figure 6B).
The dose 4 mm inside the GTV boundary (GTV - 4 mm DeIIV), relative to the GTV DV-0.01 cc (100%), and the GTV coverage value as a function of GTV (≥1.26 cc, 23 cases) are shown in Figure 7.
The GTV - 4 mm DeIIV decreased significantly as the GTV increased (Figure 7A). The GTV coverage with the GTV - 4 mm DeIIV ranged from 1.9% to 55.6%, which those were <50% in 87% of the cases (Figure 7B). The GTV - 4 mm DeIIV was significantly higher than the GTV D50% (WSRT, p < 0.001***).
The correlations between the GTV D50% and the DeIIVs of the GTV - 2 mm and GTV - 4 mm are shown in Figure 8.
No significant correlation was observed between the GTV D50% and the DeIIVs of the GTV - 2 mm (Figure 8A) and GTV - 4 mm (Figure 8B).
The correlations between the near-maximum dose of the GTV (D0.01 cc) and the DeIIVs of the GTV - 2 mm and GTV - 4 mm are shown in Figure 9.
The DeIIVs of the GTV - 2 mm (Figure 9A) and GTV - 4 mm (Figure 9B) increased significantly as the GTV D0.01 cc increased. The correlation between the DeIIV and the GTV D0.01 cc was higher in the GTV - 4 mm than in the GTV - 2 mm.
Discussion
An extremely inhomogeneous GTV dose, especially a concentrically-layered steep dose increase inside a GTV boundary, has both pros and cons. In SRS with ≥5 fractions for large BM with massive surrounding edema, tumor shape changes, including shrinking or enlargement, and/or its displacement can occur during irradiation [23-25]. If a GTV internal dose is not extremely inhomogeneous, e.g., 80% isodose coverage, tumor shrinkage and enlargement can occur with approximately equal probability [26-29]. In our experience, however, an extremely inhomogeneous GTV dose with a steep dose increase inside the GTV boundary tends to contribute to considerable tumor shrinkage during irradiation in many cases with the exception of BMs from colon and renal cell cancer [24,25,30]. Although significant tumor shrinkage during irradiation can contribute to early alleviation of the relevant symptoms, it may also increase high-dose exposures to the surrounding brain, leading to the development of symptomatic brain radionecrosis [24]. In a case with significant tumor shrinkage during multi-fraction SRS, the dose within 2-4 mm inside the GTV surface may have a greater impact on therapeutic efficacy and adverse effects than the GTV median dose (D50%) or near-maximum dose (D2% or D0.01 cc).
In VMA-based SRS with the optimization that prioritizes the steepness of dose gradient and with dose prescription of a constant BED10 at the GTV boundary, the BED10 2-4 mm inside the GTV boundary definitely decreases as the GTV increases. Furthermore, the internal BED10 decreases as the number of dose fractions increases to ensure safety for larger GTVs (Tables 1-2). The internal BED10 decline in large tumors can attenuate excessive dose exposures to the surrounding brain due to the GTV shrinkage during SRS with ≥5 fractions. However, when increasing the number of dose fractions for large tumors to ensure safety, the optimization that further increases the dose gradient inside the GTV boundary may be considered to enhance therapeutic efficacy.
In many facilities implementing linac-based SRS, dose prescription to a margin-added planning target volume boundary is common, in which the differences in marginal doses between the PTV and GTV are substantially different [5,20]. Therefore, reference to the GTV marginal dose is essential. Although D98%, D50%, and D2% of a GTV may be optimal as the representative metrics to specify the major features of the DVH curve [16], other dosimetric parameters seem to be more relevant to maximal response and local control than these metrics. The GTV DV-0.01 cc and D0.01 cc instead of the D98% and D2% may be more appropriate as the near-minimum and near-maximum doses for a GTV of >0.20 cc, respectively (D95% and D5% for GTV ≤0.20 cc) [20]. In addition, the GTV D50% has poor correlations with the doses 2 mm and 4 mm inside the GTV boundary, while the GTV D80% is too close to the GTV boundary with the irradiated isodose surface less than 1-2 mm inside the boundary. The dose within a certain distance from the GTV boundary can be an independent evaluation metric of the GTV internal dose and may be more relevant to maximal response and local control for SRS of BMs. However, given the substantial variability in the volume several millimeters inside a GTV among planning systems, the accuracy of GTV - 2 mm or 4 mm volume should be examined in advance in the system used. The DeIIV, instead of the minimum dose with a fixed percentage coverage (e.g. D98%) is suitable for reporting the dose 2 mm and 4 mm inside the GTV boundary in terms of avoiding the over- or under-coverage [20,22]. Furthermore, a high coverage value of DeIIV can be an indicator of the dose convergence inside a GTV surface. However, even with extremely inhomogeneous GTV doses, the DeIIV may be unsuitable as the evaluation metric for the doses 2-4 mm inside the GTV boundary, when the dose increase inside the GTV boundary is not concentrically layered, and the high dose area does not converge to the GTV center while being dispersed. In such cases, evaluation with the D95% of the GTV - 2 mm or 4 mm is likely appropriate instead of the DeIIV. Taken together, the importance of GTV dose metrics relevant to the maximal tumor response may be the GTV DV-0.01 cc, GTV - 2 mm DeIIV, GTV - 4 mm DeIIV, GTV D50%, and GTV D0.01 cc in order. However, evaluation with the GTV - 4 mm DeIIV is unsuitable for a GTV of ≤11-12 mm as the IIV of the GTV - 4 mm DeIIV approximates the GTV D0.01 cc. Thus, supplemental evaluation with the GTV - 4 mm DeIIV may be meaningful for a GTV of >2 cm.
This planning study was based on the results of a certain optimization method using VMA and has inherent limitations. Whether the DeIIV of GTV - 2 mm or GTV - 4 mm is clinically more relevant to maximal response and local control than the GTV D50% warrants further investigation. It is also necessary to clarify the significance of concentrically-layered steep dose increase inside a GTV boundary in maximal tumor response and to demonstrate a GTV central or maximum dose that is more than twice the GTV marginal dose being generally harmless.
Conclusions
A dose of 2 mm or 4 mm inside a GTV surface has a low correlation with the GTV D50% or other minimum dose with a fixed coverage. The dose within a certain distance from the GTV boundary can be an independent evaluation metric of the GTV internal dose. The DeIIV instead of the minimum dose of a fixed percentage coverage (e.g. D98%) is suitable as the representative index in terms of avoiding over- or under-coverage. The DeIIV of GTV - 2 mm and GTV - 4 mm may be more relevant to maximal response and local control for SRS of BM, in which the high coverage value can reflect high dose convergence inside the GTV. In VMA-based SRS with a steep dose gradient, the doses 2-4 mm inside a GTV decrease significantly as the GTV increases, which can attenuate excessive dose exposures to the surrounding brain due to the GTV shrinkage during SRS with ≥5 fractions.
Acknowledgments
The authors are grateful to Dr. Yukihiko Oshima and Ms. Noriko Tazawa (Department of Radiology, Aichi Medical University) for their valuable support and contributions.
Funding Statement
This study was supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI Grant-in-Aid for Scientific Research with grant number 21K07561.
Disclosures
Human subjects: Consent was obtained or waived by all participants in this study. Clinical Research Review Board of Kainan Hospital Aichi Prefectural Welfare Federation of Agricultural Cooperatives issued approval 20220727-1.
Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue.
Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following:
Payment/services info: This study was supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI Grant-in-Aid for Scientific Research with grant number 21K07561.
Financial relationships: Kazuhiro Ohtakara and Kojiro Suzuki declare(s) a grant from Japan Society for the Promotion of Science (JSPS).
Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
Author Contributions
Concept and design: Kazuhiro Ohtakara, Kojiro Suzuki
Acquisition, analysis, or interpretation of data: Kazuhiro Ohtakara
Drafting of the manuscript: Kazuhiro Ohtakara
Critical review of the manuscript for important intellectual content: Kazuhiro Ohtakara, Kojiro Suzuki
Supervision: Kojiro Suzuki
References
- 1.Stereotactic radiosurgery and stereotactic fractionated radiotherapy in the management of brain metastases. Benkhaled S, Schiappacasse L, Awde A, Kinj R. Cancers (Basel) 2024;16:1093. doi: 10.3390/cancers16061093. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Fifteen-fraction radiosurgery followed by reduced-dose whole-brain irradiation with a total biologically effective dose of >90-100 Gy for a locally invasive brain metastasis from lung adenocarcinoma with a high dissemination potential. Ohtakara K, Ohka F, Tanahashi K, Yamada T, Suzuki K. Cureus. 2023;15:0. doi: 10.7759/cureus.49596. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Overall survival following stereotactic radiosurgery for ten or more brain metastases: a systematic review and meta-analysis. Rozati H, Chen J, Williams M. BMC Cancer. 2023;23:1004. doi: 10.1186/s12885-023-11452-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Consideration of optimal isodose surface selection for target coverage in micro-multileaf collimator-based stereotactic radiotherapy for large cystic brain metastases: comparison of 90%, 80% and 70% isodose surface-based planning. Ohtakara K, Hayashi S, Tanaka H, Hoshi H. Br J Radiol. 2012;85:0–6. doi: 10.1259/bjr/21015703. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Tumor control probability of radiosurgery and fractionated stereotactic radiosurgery for brain metastases. Redmond KJ, Gui C, Benedict S, et al. Int J Radiat Oncol Biol Phys. 2021;110:53–67. doi: 10.1016/j.ijrobp.2020.10.034. [DOI] [PubMed] [Google Scholar]
- 6.Modified dynamic conformal arcs with forward planning for radiosurgery of small brain metastasis: each double arc and different to-and-fro leaf margins to optimize dose gradient inside and outside the gross tumor boundary. Ohtakara K, Suzuki K. Cureus. 2023;15:0. doi: 10.7759/cureus.34831. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.An extremely inhomogeneous gross tumor dose is suitable for volumetric modulated arc-based radiosurgery with a 5-mm leaf-width multileaf collimator for single brain metastasis. Ohtakara K, Suzuki K. Cureus. 2023;15:0. doi: 10.7759/cureus.35467. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Internal dose escalation is associated with increased local control for non-small cell lung cancer (NSCLC) brain metastases treated with stereotactic radiosurgery (SRS) Abraham C, Garsa A, Badiyan SN, et al. Adv Radiat Oncol. 2018;3:146–153. doi: 10.1016/j.adro.2017.11.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Inhomogeneous tumor dose distribution provides better local control than homogeneous distribution in stereotactic radiotherapy for brain metastases. Lucia F, Key S, Dissaux G, et al. Radiother Oncol. 2019;130:132–138. doi: 10.1016/j.radonc.2018.06.039. [DOI] [PubMed] [Google Scholar]
- 10.Internal dose escalation associated with increased local control for melanoma brain metastases treated with stereotactic radiosurgery. Kennedy WR, DeWees TA, Acharya S, et al. J Neurosurg. 2020;135:855–861. doi: 10.3171/2020.7.JNS192210. [DOI] [PubMed] [Google Scholar]
- 11.Feasibility and potential advantages using VMAT in SRS metastasis treatments. Perez-Calatayud MJ, Menendez AV, Celada-Alvarez FJ, et al. Rep Pract Oncol Radiother. 2021;26:119–127. doi: 10.5603/RPOR.a2021.0019. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Volumetric reduction of brain metastases after stereotactic radiotherapy: prognostic factors and effect on local control. Kanayama N, Ikawa T, Ohira S, et al. Cancer Med. 2022;11:4806–4815. doi: 10.1002/cam4.4809. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Feasibility of a simultaneously integrated boost concept for hypofractionated stereotactic radiotherapy of unresected brain metastases. Kornhuber C, Ensminger S, Hübsch P, Janich M, Leucht CA, Vordermark D, Dietzel CT. Radiat Oncol. 2023;18:88. doi: 10.1186/s13014-023-02266-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.The dosimetric parameters impact on local recurrence in stereotactic radiotherapy for brain metastases. Berthet C, Lucia F, Bourbonne V, et al. Br J Radiol. 2024;97:820–827. doi: 10.1093/bjr/tqae029. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Effect of prescription isodose line on tissue sparing in linear accelerator-based stereotactic radiosurgery treating multiple brain metastases using dynamic conformal arcs. Walter YA, Dugas JP, Broekhoven BL, Jacobs TD, Han M, Wang CJ, Wu HT. J Appl Clin Med Phys. 2024;25:0. doi: 10.1002/acm2.14278. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.ICRU Report 91: prescribing, recording, and reporting of stereotactic treatments with small photon beams. Seuntjens J, Lartigau EF, Cora S, et al. https://journals.sagepub.com/toc/crua/14/2 J ICRU. 2014;14:1–160. [Google Scholar]
- 17.Characterisation of dose distribution in linear accelerator-based intracranial stereotactic radiosurgery with the dynamic conformal arc technique: consideration of the optimal method for dose prescription and evaluation. Ohtakara K, Hayashi S, Hoshi H. Br J Radiol. 2012;85:69–76. doi: 10.1259/bjr/20905396. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Feasibility of single-isocenter, multi-arc non-coplanar volumetric modulated arc therapy for multiple brain tumors using a linear accelerator with a 160-leaf multileaf collimator: a phantom study. Iwai Y, Ozawa S, Ageishi T, Pellegrini R, Yoda K. J Radiat Res. 2014;55:1015–1020. doi: 10.1093/jrr/rru042. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Stereotactic radiotherapy planning using modified dynamic conformal arcs under considering the possibility for amended visual organ displacement resulting from early tumor shrinkage during treatment for perioptic involvement of myeloma. Ohtakara K, Hoshi H. Int J Med Phys Clin Eng Radiat Oncol. 2014;3:183–192. [Google Scholar]
- 20.Proposal of an alternative near-minimum isodose surface DV-0.01 cc equally minimizing gross tumor volume below the relevant dose as the basis for dose prescription and evaluation of stereotactic radiosurgery for brain metastases. Ohtakara K, Suzuki K. Cureus. 2024;16:0. doi: 10.7759/cureus.57580. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Ten-fraction stereotactic radiosurgery with different gross tumor doses and inhomogeneities for brain metastasis of >10 cc: treatment responses suggesting suitable biological effective dose formula for single and 10 fractions. Ohtakara K, Nakabayashi K, Suzuki K. Cureus. 2023;15:0. doi: 10.7759/cureus.34636. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Appropriateness of dose attenuation margin outside the gross tumor volume (GTV) in volumetric-modulated arc-based radiosurgery for brain metastasis with the steepest dose gradient outside the GTV and biologically effective dose 80 Gy to GTV boundary. Ohtakara K, Suzuki K. Cureus. 2024;16:0. doi: 10.7759/cureus.62784. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Target volume geometric change and/or deviation from the cranium during fractionated stereotactic radiotherapy for brain metastases: potential pitfalls in image guidance based on bony anatomy alignment. Ohtakara K, Hoshi H. J Med Imaging Radiat Oncol. 2014;58:729–736. doi: 10.1111/1754-9485.12194. [DOI] [PubMed] [Google Scholar]
- 24.Correlation of brain metastasis shrinking and deviation during 10-fraction stereotactic radiosurgery with late sequela: suggesting dose ramification between tumor eradication and symptomatic radionecrosis. Ohtakara K, Tanahashi K, Kamomae T, Miyata K, Suzuki K. Cureus. 2023;15:0. doi: 10.7759/cureus.33411. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Local control failure after five-fraction stereotactic radiosurgery alone for symptomatic brain metastasis from squamous cell lung carcinoma despite 43 Gy to gross tumor margin with internal steep dose increase and tumor shrinkage during irradiation. Ohtakara K, Tanahashi K, Kamomae T, Ito E, Suzuki K. Cureus. 2023;15:0. doi: 10.7759/cureus.38645. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Interfractional target changes in brain metastases during 13-fraction stereotactic radiotherapy. Uto M, Ogura K, Katagiri T, Takehana K, Mizowaki T. Radiat Oncol. 2021;16:140. doi: 10.1186/s13014-021-01869-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Interfractional change of tumor volume during fractionated stereotactic radiotherapy using gamma knife for brain metastases. Kawashima M, Akabane A, Noda R, Segawa M, Tsunoda S, Inoue T. J Neurooncol. 2022;159:409–416. doi: 10.1007/s11060-022-04075-8. [DOI] [PubMed] [Google Scholar]
- 28.5-fraction re-radiosurgery for progression following 8-fraction radiosurgery of brain metastases from lung adenocarcinoma: importance of gross tumor coverage with biologically effective dose ≥80 Gy and internal dose increase. Ohtakara K, Tanahashi K, Kamomae T, Suzuki K. Cureus. 2023;15:0. doi: 10.7759/cureus.42299. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Volumetric-modulated arc-based re-radiosurgery with simultaneous reduced-dose whole-brain irradiation for local failures following prior radiosurgery of brain oligometastases from small cell lung cancer. Ohtakara K, Arakawa S, Nakao M, Muramatsu H, Suzuki K. Cureus. 2023;15:0. doi: 10.7759/cureus.44492. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Gradual and remarkable tumor shrinkage following seven-fraction stereotactic radiosurgery alone with a marginal dose of 48.3 Gy for large lobar possibly intra-sulcal brain metastasis from renal cell carcinoma. Ohtakara K, Aoki S, Tajima M, Ohno T, Suzuki K. Cureus. 2023;15:0. doi: 10.7759/cureus.36346. [DOI] [PMC free article] [PubMed] [Google Scholar]